1256387 87 7 Ledipasvir Intermediates GMP standard C24H34BN3O4

CAS : 1256387-87-7  Ledipasvir Intermediates GMP standard C24H34BN3

Chemical Name : ( 1R , 3S , 4S ) - 3 - [ 6 - ( 4 , 4 , 5 , 5 - Tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) - 1H - benzimidazol - 2 - yl ] - 2 - azabicyclo [2 . 2 . 1 ] heptane - 2 - carboxylic acid 1 , 1 - dimethylethyl ester

CAS No . : 1256387-87-7

Molecular Formula : C24H34BN3O4

Molecular Weight : 439.36

Usage : Ledipasvir Intermediate

Description :

Ledipasvir developped by Gilead Sciences is used to treat Hepatitis C. Ledipasvir is a inhibitor of a hepatitis C virus protein called NS5A. It is used together with another drug called Sofosbuvir. The fixed dose - combination tablet Ledipasvir / Sofosbuvir was approved by US FDA in February 10 , 2014 . The brand name of the combination product Ledipasvir / Sofosbuvir is Harvoni. It is used for genotpye 1 Hepatitis C.

( 1R , 3S , 4S ) - 3 - [ 6 - ( 4 , 4 , 5 , 5 - Tetramethyl - 1 , 3 , 2 - dioxaborolan - 2 - yl ) - 1H - benzimidazol - 2 - yl ] - 2 - azabicyclo [2 . 2 . 1 ] heptane - 2 - carboxylic acid 1 , 1 - dimethylethyl ester CAS No . : 1256387-87-7 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our commercial products are manufactured without infringing such patents. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.